Intravenous ribavirin was given to nine patients who had developed severe adenovirus-induced hemorrhagic cystitis (AD-HC) which was resistant to conventional therapy or where there was involvement of other organs after allogeneic BMT. Three patients recovered completely from AD-HC, two of whom had been resistant to vidarabine. All three had received sibling BMTs (2 HLA matched, 1 HLA mismatched). Five patients who received BMTs from related (2 HLA mismatched) or unrelated (1 HLA matched, 2 HLA mismatched) showed an improvement in symptoms but had recurrent AD-HC after discontinuation of ribavirin. Improvement in clinical symptoms and termination of virus excretion were well correlated. The last patient who received a mismatched unrelated BMT died during ribavirin therapy. Ribavirin was notably more effective among patients receiving BMTs from siblings in contrast to patients receiving BMTs from alternative donors (Ͻ0.05). One patient experienced severe pancytopenia during the second treatment with ribavirin after HC recurrence and recovered after ceasing ribavirin. Thus, ribavirin seems to be very effective for severe AD-HC for some recipients who receive transplants from a genetically close donor. Bone Marrow Transplantation (2000) 25, 545-548.
Hemorrhagic cystitis (HC) is a complication seen after bone marrow transplantation (BMT), occurring in 6.5-52% of transplant patients. [1] [2] [3] [4] While HC has been reported after bladder injury by cyclophosphamide, increased risk of HC has also been recognized in association with virus infection, including adenovirus and BK (polymer-like) virus. 2, 5 Adenovirus-induced hemorrhagic cystitis (AD-HC) was first reported in Japan in 1968 as the causative agent for sporCorrespondence: Dr K Miyamura, First Department of Internal Medicine, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan Received 26 March 1999; accepted 5 September 1999 adic infantile hemorrhagic cystitis. 6 AD-HC has also been reported in immunocompromised adults, such as postchemoradiotherapy cancer patients or post-renal transplantation. 7, 8 Our group and others have reported AD-HC after allogeneic BMT from a sibling donor. [9] [10] [11] All these AD-HC cases were associated with adenovirus type 11, and to a lesser extent, with types 21, 30, 34 and 35. A positive relationship was observed between the occurrence of acute graft-versus-host disease (aGVHD) and that of AD-HC.
2,11,12 AD-HC was also reported after autologous BMT, but the incidence was lower. 13 After autologous BMT and allogeneic BMT from sibling donors, AD-HC was generally self-limiting, and patients recovered with supportive care such as red blood cell transfusions and analgesia. 2 Recently, allogeneic BMT from unrelated donors has become feasible and numbers have increased. In BMT from unrelated donors, patients suffer more profound immunosuppression because of more severe GVHD and subsequent high doses of immunosuppressants. Thus, an increased incidence of virus infections and more severe symptoms have been reported. 12, 14 We have recently observed life-threatening AD-HC in unrelated transplant recipients. AD-HC in such patients usually persisted during observation and supportive care. Most patients subsequently developed adenovirus-induced pneumonia, renal infection or systemic infections, all of which were potentially fatal. When AD-HC is resistant to conventional therapies, further treatment is controversial. 15 We treated these patients with intravenous ribavirin.
Ribavirin is a broad-spectrum antiviral agent that is active against adenovirus infections in vitro. Experience with administration of intravenous ribavirin for severe AD-HC has been reported. Most accounts have shown its usefulness, while two accounts reported failures. [16] [17] [18] [19] [20] [21] However, five reports dealt with only a single case and did not offer sufficient data regarding use and toxicity of intravenous ribavirin after BMT. Here, we report the results after administration of ribavirin to nine patients resistant to conventional therapy.
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Patients and methods
Patient characteristics
Six patients from the Japanese Red Cross Nagoya First Hospital and one from Meitetsu Hospital, Harasanshin Hospital and the Chiba University School of Medicine were entered into this study. Characteristics of these patients are shown in Table 1 . Five were male and four were female; ages ranged from 14 to 34 years. All had hematological malignancies (four acute lymphocytic leukemia, two acute myeloid leukemia, two chronic myelogenous leukemia and one malignant lymphoma). Two patients received BMT for chronic phase CML and first remission AML and the other seven received BMTs in the later phases of their disease.
Bone marrow transplantation procedures
Two patients received a preparative regimen consisting of cyclophosphamide (120 mg/kg) and mesna. Two received BMT from an HLA-identical sibling, two from an HLAmismatched sibling, one from his three loci mismatched father, one from an HLA phenotypically matched unrelated donor, and three received HLA-mismatched unrelated donor marrow. Two patients received anti-T lymphocyte immunoglobulin with the preparative regimen and two received it therapeutically for aGVHD. One received Tlymphocyte-depleted marrow by anti-pan T lymphocyte monoclonal antibodies (MoAbs). 22 Short-course methotrexate plus either cyclosporine or FK506 were used for the prophylaxis of aGVHD. For the treatment of aGVHD, low- 
Diagnosis of adenovirus hemorrhagic cystitis and administration of ribavirin
A diagnosis of HC was made when a patient demonstrated the clinical signs of both cystitis and macroscopic hematuria. Adenovirus HC was diagnosed when the disease was accompanied by adenovirus viruria. The method of isolating the adenovirus has been previously reported. 2 Intravenous ribavirin was obtained from ICN Pharmaceuticals (Costa Mesa, CA, USA). Ribavirin was used for the patients whose HC met two of these three criteria: (1) severe HC requiring red blood transfusion and analgesics; (2) HC persisting for more than 4 weeks; (3) suspicion of further adenovirus infection in another site. After informed consent, nine patients received ribavirin therapy for severe AD-HC. Two received a second ribavirin course on recurrence of AD-HC after finishing the first course. Ribavirin was administered to the adult patients intravenously by i.v. infusion for 15 min at 16 mg/kg every 6 h for 4 days followed by 8 mg/kg every 8 h for 3 days. For children, ribavirin was given at dose of 15 mg/kg per day for 10 days. Response to the intravenous ribavirin was assessed by improvement in clinical symptoms and decrease in supportive care requirement.
Results
Initial therapy
Nine patients received intravenous ribavirin under the conditions mentioned above. The onset of initial HC occurred from 20 to 117 days after BMT. All patients received conservative therapies such as blood transfusions, bladder irrigation and anesthesia. Three received oral vidarabine therapy for more than a week. In spite of therapy, all patients suffered prolonged severe HC.
Clinical symptoms other than HC
Three patients suffered from high-grade fever during AD-HC, resistant to antibiotics, and were suspected of having a systemic adenovirus infection. In one patient, hemorrhagic pneumonia occurred almost simultaneously with AD-HC. One patient developed bronchitis during AD-HC. All these symptoms seemed to be related to the adenovirus infection because they improved soon after commencement of ribavirin, although virus isolation from the suspected sites had not been performed.
Efficacy of intravenous ribavirin
Three patients had good responses to intravenous ribavirin and recovered completely. Clinical symptoms improved several days after ribavirin was started. The concurrent hemorrhagic pneumonia observed in one of these patients also resolved after administration of ribavirin. Virus iso-lation was negative 9 and 53 days after ribavirin therapy in one patient. In the second patient, adenovirus was still isolated from the urine 11 days after ribavirin therapy. However, no virus was isolated 47 days after therapy. The third patient had no further virus isolated after therapy. The remaining five patients had partial responses. Improvements in the clinical symptoms of HC, fever (2) and bronchitis (1) were observed. Recurrence of AD-HC was observed after discontinuation of ribavirin. Among these five patients, two had virus isolated during their clinical response. They had negative results 9, 26 and 14 days after the ribavirin therapy, respectively. They excreted adenovirus again when HC recurred. These five patients eventually died of adenovirus nephritis (2), encephalitis (1), interstitial pneumonia (1) and bacterial pneumonia (1). The last patient died during ribavirin administration from disease progression.
Toxicity of intravenous ribavirin
One patient developed severe pancytopenia during the second ribavirin course for a recurrence of AD-HC. Hematological recovery took place after discontinuation of ribavirin. One patient developed hemolytic anemia 14 days after the cessation of ribavirin.
Response to ribavirin and clinical parameters
Patients were divided into two groups according to mortality. Three patients survived AD-HC (group A) and the other six died during AD-HC (group B). It is important to note that all patients in group A received BMT from siblings, while of those in group B, only one patient received a BMT from a sibling (P = 0.02) ( Table 2 ). Although only one of three patients in group A had grade 2 or greater aGVHD, three out of six in group B developed it (P = 0.63). One of three patients in group A received in vitro or in vivo purging of T lymphocytes, while four of six in group B did so (P = 0.24).
Discussion
In the current clinical study, it was demonstrated that ribavirin seems to be effective against adenovirus infection after BMT. Improvements in clinical symptoms such as HC, high-grade fever and pulmonary complications were found in eight of nine patients. However, only three patients recovered from AD-HC completely. The other five patients who had received BMTs from other than HLA-identical Thus, in the current study, the efficacy of ribavirin seems to depend on the genetic differences between patient and donor. Five case reports of intravenous ribavirin therapy after BMT have been published. [16] [17] [18] 20, 21 Four patients recovered from the disease completely and one showed no sign of improvement after 5 days of therapy and died of encephalitis. In addition, Hromas et al 19 reported three failed cases of AD-HC after T cell-depleted unrelated BMT. 19 Among four patients who improved, three received BMTs from other than an HLA-identical sibling. Thus, in spite of the current study results, ribavirin may be worth trying in such patients. However, it is not appropriate to draw conclusions from the few scattered cases from different centers.
Intravenous ribavirin is reported to be relatively safe, with adverse effects limited to reversible dose-related macrocytic anemia as seen in the treatment of Lassa fever. 23 No significant toxicity from ribavirin was found in the previous case reports, while in the current series, severe myelosuppression was observed after a second administration of intravenous ribavirin following recurrent AD-HC. Marrow aspiration showed severe hypoplasia of hematopoietic precursors. Myelosuppression recovered after the termination of ribavirin therapy. In the setting of hematopoietic stem cell transplantation, myelosuppression should be a concern when intravenous ribavirin is used.
Patients whose AD-HC is resistant to ribavirin therapy need alternative therapies such as donor lymphocyte infusion or the generation of cytotoxic T lymphocytes against adenovirus. 24, 25 Thus, the current results suggest a distinct treatment approach according to the genetic disparities between patient and donor. However, to clarify these issues, larger prospective studies including sequential virus isolation will be required.
